GENinCode PLC Grant of Share Options and PDMR dealing (1613M)

TIDMGENI

RNS Number : 1613M

GENinCode PLC

17 September 2021

17 September 2021

GENinCode Plc

("GENinCode" or the "Company")

Grant of Share Options and PDMR dealing

GENinCode Plc (AIM:GENI), Oxford, UK, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today that the Remuneration Committee has recommended, and the Board has approved, to issue options over a total of 572,000 ordinary shares of GBP0.01 each in the capital of the Company ("Share Options").

The Share Options have been issued in line with the Company's existing share option plan to Paul Foulger, a director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Paul Foulger on 15 April 2021 and combined, the number of ordinary shares held under option by Paul Foulger is 1,144,000, representing 1.19% of the existing issued ordinary share capital of the Company.

The Share Options are exercisable once the average market value of the Company's shares for a period of 30 consecutive dealing days following the date of the issue of the Share Options first exceeds two times the exercise price of GBP0.44.

Contacts:

 
 GENinCode plc                                                                   www.genincode.com 
 Matthew Walls, CEO                                                                Via Walbrook PR 
 Paul Foulger, CFO 
 
 Stifel Nicolaus Europe Limited (Nomad and                                Tel: [phone] 
  Joint Broker) 
 Alex Price / Ben Maddison / Richard 
  Short 
 
 Cenkos Securities Plc (Joint Broker)                                     Tel: [phone] 
 Giles Balleny 
 Dale Bellis / Michael Johnson (Sales) 
 
 Walbrook PR Limited                               Tel: [phone] or genincode @walbrookpr.com 
 Anna Dunphy / Paul McManus / Louis 
  Ashe-Jepson 
 
 

About GENinCode plc

GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease ("CVD"). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company's products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.

The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode(R), Lipid inCode(R), Thrombo inCode(R) and Sudd inCode(R). The Directors believe that approximately EUR50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

DIRECTOR/PDMR SHAREHOLDING

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                Paul Foulger 
     ------------------  --------------------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status     CFO 
     ------------------  --------------------------------------------------- 
 b)   Initial             Initial Notification 
       notification/ 
       Amendment 
     ------------------  --------------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                GENinCode Plc 
     ------------------  --------------------------------------------------- 
 b)   LEI                 213800UX6TE7K65O2892 
     ------------------  --------------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description         Ordinary Shares of GBP0.01p 
       of the 
       financial 
       instrument, 
       type of             GB00BL97B504 
       instrument 
       Identification 
       code 
     ------------------  --------------------------------------------------- 
 b)   Nature              Grant of conditional shares in the Company's Share 
       of the              Option Scheme 
       transaction 
     ------------------  --------------------------------------------------- 
 c)   Price(s)              Exercise    Volume 
       and volume(s)          Price 
                             GBP0.44     572,000 
                                        -------- 
     ------------------  --------------------------------------------------- 
 d)   Aggregated 
       information 
       - Aggregated         N/A - single transaction 
       volume 
       - Price 
     ------------------  --------------------------------------------------- 
 e)   Date of              17 September 2021 
       the transaction 
     ------------------  --------------------------------------------------- 
 f)   Place                Outside a trading venue 
       of the 
       transaction 
     ------------------  --------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSFLSUWEFSEDU

(END) Dow Jones Newswires

September 17, 2021 05:38 ET (09:38 GMT)